🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

INVENTURUS KNOWLEDGE SO L IKS NIFTY_SMALLNSEPHARMA

Healthcare · Health Information Services · India
https://ikshealth.com
Company Profile ↓
₹1,759.90
+13.98% 1Y
Mkt Cap₹30,195.16 Cr
P/E41.64
P/B10.38
52W High₹1,928.10
52W Low₹1,274.90
Book Value₹163.21
EPS (TTM)₹42.26

Company Overview

Inventurus Knowledge Solutions Limited operates as a technology-enabled healthcare solutions provider. The company offers a care enablement platform that assists physician businesses in outpatient and inpatient care activities in the United States, Canada, and Australia. The company offers a platform that serves healthcare organizations, including health systems/ integrated delivery networks, academic medical centers, multi-specialty medical groups, single-specialty medical groups, ancillary healthcare organizations, and other outpatient healthcare delivery organizations. Inventurus Knowledge Solutions Limited was incorporated in 2006 and is based in Navi Mumbai, India.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 25.8%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 29.6%.

Consistent Profit Growth

Net profit has compounded at 33.2% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 45.8% CAGR over the past five years.

Healthy Margins

Maintains a net profit margin of 22.6%.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.27.

Recent Developments

  • Mar 2026 Revenue of ₹3,193.79 Cr (+19.9% YoY); net profit ₹721.55 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +19.9%, earnings +48.4%.
  • 5-Year Trend Long-term compounding — revenue CAGR 45.8%, profit CAGR 33.2%.

Growth & Price Performance

Compounded Sales Growth

5 Years:45.76%
1 Year:19.89%

Compounded Profit Growth

5 Years:33.21%
1 Year:48.45%

Stock Price Performance

1 Year:+13.98%
6 Months:+32.40%
3 Months:+4.54%
1 Month:-0.18%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 74% of range
₹1,274.90 ₹1,928.10
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMAAbove
  • RSI (14)46.92 · Neutral
Price Performance
1M-0.18%
3M+4.54%
6M+32.40%
1Y+13.98%
Valuation vs Sector

P/E of 41.64 is above the sector median of 41.64 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 25.8%.
  • Healthy ROCE of 29.6%.
  • Excellent profit margin of 22.6%.
  • Compounding revenue at 45.8% over 5 years.
  • Profit CAGR of 33.2% over 5 years.
  • Generates positive free cash flow.

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
41.64
Industry PE
41.64
Forward P/E
30.21
PEG Ratio
-
Book Value
₹163.21
Price to Book
10.38
P/S
9.13
EV/EBITDA
28.92
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
45.76%
Profit 5Y
33.21%
Revenue (YoY)
19.89%
Earnings (YoY)
48.45%

Profitability & Returns

ROCE
29.57%
ROE
25.77%
ROA
16.91%
Profit Margin
22.59%
Op Margin
30.28%
Gross Margin
49.00%
EPS (Latest Qtr)
₹11.32
EPS (TTM)
₹42.26

Balance Sheet & Liquidity

Debt/Equity
0.27
Quick Ratio
1.35
Current Ratio
1.35
Debt
₹752.51 Cr
Total Assets
₹4,267.88 Cr
Current Assets
₹1,309.64 Cr
Working Capital
₹339.59 Cr

Ownership

Promoter Holding
70.98%
Chg in Prom Hold
-2.36%
FII / Inst Holding
9.94%
Chg in FII Hold
0.09%

Financial Snapshot

Enterprise Value
₹30,195.16 Cr
Total Revenue (TTM)
₹3,193.79 Cr
EBITDA
₹1,099.31 Cr
Free Cash Flow
₹612.95 Cr
Operating Cash Flow
₹673.59 Cr
Shares Outstanding
₹17.16 Cr
Gross Margin
49.00%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 IKS INVENTURUS KNOWLEDGE SO L NIFTY_SMALLNSEPHARMA 1,759.90 41.64 ₹30,195.16 Cr 0.00% 29.57% 25.77% 45.76% 33.21%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,899.00 39.73 ₹4.56 L Cr 0.82% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,100.00 94.06 ₹2.42 L Cr 0.36% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,857.00 75.99 ₹1.64 L Cr 0.77% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,650.00 64.10 ₹1.24 L Cr 0.22% 19.20% 20.48% 14.85% 33.34%
6 LENSKART LENSKART SOLUTIONS LTD NIFTY_MIDNSEPHARMA 684.90 236.17 ₹1.19 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,120.00 22.36 ₹1.13 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,385.00 28.85 ₹1.12 L Cr 0.88% 14.86% 11.27% 7.23% 11.45%
9 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 1,840.00 111.85 ₹99,333.61 Cr 0.13% 19.53% 16.77% 3.77% 4.00%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue 567.00 Cr620.00 Cr640.00 Cr643.00 Cr657.16 Cr723.96 Cr740.10 Cr781.00 Cr814.95 Cr857.65 Cr893.63 Cr
Cost of Revenue ----383.37 Cr386.55 Cr395.96 Cr-405.91 Cr419.75 Cr454.85 Cr
Gross Profit ----273.79 Cr337.41 Cr344.13 Cr-409.04 Cr437.90 Cr438.78 Cr
Operating Expenses 405.00 Cr494.00 Cr467.00 Cr454.00 Cr120.08 Cr139.56 Cr134.28 Cr511.00 Cr159.49 Cr171.73 Cr178.13 Cr
Operating Income 143.00 Cr99.00 Cr145.00 Cr161.00 Cr153.71 Cr197.84 Cr209.85 Cr240.00 Cr249.56 Cr266.17 Cr260.65 Cr
EBITDA 162.00 Cr126.00 Cr173.00 Cr189.00 Cr208.45 Cr229.44 Cr240.86 Cr270.00 Cr284.76 Cr299.69 Cr295.34 Cr
Interest Expense 26.00 Cr32.00 Cr26.00 Cr22.00 Cr20.54 Cr21.02 Cr18.08 Cr16.00 Cr23.34 Cr12.68 Cr10.11 Cr
Pretax Income 124.00 Cr81.00 Cr122.00 Cr144.00 Cr160.16 Cr180.09 Cr194.88 Cr228.00 Cr229.37 Cr252.96 Cr250.94 Cr
Tax Provision 22.32 Cr17.01 Cr26.84 Cr30.24 Cr30.48 Cr32.28 Cr43.34 Cr47.88 Cr46.04 Cr46.99 Cr57.20 Cr
Net Income 102.00 Cr64.00 Cr95.00 Cr113.00 Cr129.68 Cr147.80 Cr151.54 Cr181.00 Cr183.33 Cr205.97 Cr193.74 Cr
Diluted EPS 5.943.725.576.597.608.708.8510.5310.7312.0611.32

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 529.00 Cr553.00 Cr-1,031.30 Cr1,816.91 Cr2,663.99 Cr3,193.79 Cr
Cost of Revenue ---509.31 Cr974.79 Cr1,495.35 Cr1,628.67 Cr
Gross Profit ---521.99 Cr842.12 Cr1,168.64 Cr1,565.11 Cr
Operating Expenses 367.00 Cr348.00 Cr-151.37 Cr376.05 Cr511.59 Cr597.92 Cr
Operating Income 122.00 Cr175.00 Cr-370.62 Cr466.07 Cr657.05 Cr967.19 Cr
EBITDA 162.00 Cr205.00 Cr-389.26 Cr559.16 Cr808.71 Cr1,099.31 Cr
Interest Expense 7.00 Cr8.00 Cr-5.36 Cr58.94 Cr89.77 Cr70.25 Cr
Pretax Income 145.00 Cr183.00 Cr-359.34 Cr441.67 Cr606.28 Cr904.91 Cr
Tax Provision 7.25 Cr16.47 Cr-54.12 Cr71.18 Cr120.22 Cr183.36 Cr
Net Income 137.00 Cr165.00 Cr-305.23 Cr370.49 Cr486.06 Cr721.55 Cr
Diluted EPS 166.73200.10-17.7921.5928.6242.26

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025Mar 2026
Total Assets 434.00 Cr586.00 Cr-988.31 Cr3,027.52 Cr3,051.84 Cr3,606.00 Cr4,267.88 Cr
Current Assets ---698.19 Cr897.79 Cr783.87 Cr-1,309.64 Cr
Cash & Equivalents ---123.62 Cr143.81 Cr180.42 Cr-388.72 Cr
Inventory ---074.70 L0-5.80 L
Receivables ---154.96 Cr353.94 Cr450.03 Cr-564.48 Cr
Total Liabilities ---159.67 Cr1,869.66 Cr1,262.14 Cr-1,467.64 Cr
Current Liabilities ---114.94 Cr790.02 Cr521.18 Cr-970.05 Cr
Long Term Debt ---0812.33 Cr509.27 Cr-274.99 Cr
Total Debt 076.00 Cr-52.35 Cr1,311.09 Cr855.62 Cr766.00 Cr752.51 Cr
Total Equity 283.00 Cr457.00 Cr-828.64 Cr1,157.86 Cr1,789.69 Cr2,241.00 Cr2,800.24 Cr
Shares Outstanding ---16.67 Cr16.67 Cr17.16 Cr-17.16 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 163.00 Cr175.00 Cr-287.98 Cr209.77 Cr317.89 Cr673.59 Cr
Investing Cash Flow -79.00 Cr-167.00 Cr--155.96 Cr-1,141.28 Cr244.45 Cr-210.00 Cr
Financing Cash Flow -41.00 Cr-37.00 Cr--152.19 Cr780.37 Cr-389.49 Cr-411.80 Cr
Capital Expenditure -11.00 Cr-7.00 Cr--8.55 Cr-32.71 Cr-42.38 Cr-60.64 Cr
Free Cash Flow 152.00 Cr168.00 Cr-279.43 Cr177.06 Cr275.51 Cr612.95 Cr
Net Change in Cash 43.00 Cr-28.00 Cr--20.17 Cr-151.14 Cr172.85 Cr51.78 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % ---50.6%46.3%43.9%49.0%
Operating Margin % 23.1%31.6%-35.9%25.7%24.7%30.3%
Net Margin % 25.9%29.8%-29.6%20.4%18.2%22.6%
ROE % 48.4%36.1%-36.8%32.0%27.2%25.8%
ROCE % ---42.4%20.8%26.0%29.3%

Shareholding Pattern

Insiders
70.98%
Institutions
9.94%
Public Float
34.24%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for IKS

Google News Sat, 11 Jul 2026

TruBridge (TBRG) Stock Gets Fair Value Boost As Analysts Weigh IKS Deal Risks - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxOM085WWpBTmFNd2ZHRVNLbjlhNTlWUEVEbmswaC1Rdk55aDc3Z1dIMzVaN3o2SW9WX2VyZ2UweFVpUzZiaklBdTdsdWFhaWRKUXZKZTJCSXBIbzhqUW9zU05kdFFRZXlEaDVIVkc4LTBuQWRNTDdKNklZRUFpSHJIOTkzazlBVnBOOXJMMT…

Google News hu, 23 Apr 2026

IKS Health Announces Agreement to Acquire TruBridge to Strengthen Access to Rural and Community-Based Healthcare - businesswire.com

<a href="https://news.google.com/rss/articles/CBMi_gFBVV95cUxQNFFLNDJXUVlfZDJTT0hDeFN4bFc3Tkl6QlRSN2R4OGRpWjhWLTdYMXl4RDZvY05rLTB1aEdHVHNYV3djZnB2QURsU1A3VlN2dTN5M2hzZ0UtVzNKT1pXUWp3MGN0NG9HMHNxeDN4X2pIbDBfNExDem50aXFBWm9qRGhzbkcyM0QyZnVFMl…

Google News Mon, 07 Sep 2026

ICICIdirect.com Starts Inventurus Knowledge Solutions at Buy with INR2,110 Price Target - marketscreener.com

<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxOZDc0UWFiWGc1UnlwT0Z1a2x4b0x3Y2o3cU1IRWcwdEJrTjVsUlFZRGhFZ3RnVHdra3RpZFVFUEhlSldYSzAtR1BKRllWUnJ2eTFtUTVlWHA5TTYxUXNFY2VQRUtCUXR1R1N0SlA0cHUyTlpFbVhMU0ExWnd5c1p0MWhVWUtjZjZRb0tmdl…

Google News Mon, 07 Sep 2026

INVENTURUS KNOWLEDGE SO L Share Price News After Fresh Gain - Univest

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxPYmcwYmdILXNJN0hOR1hNR1BNOWszYUFfQXdwakRqOWpURFVWUExhaFUtSk54bks3b29QRC1Rd2lNYUctRFNIYVV6bXVzSWYzLUpacW44ckZHUUJibXRuaHFiZDdVVHlVUTFhWkZJdEY0d0k4MnhyQm1EdWt2ZnNKdGlVR2I1cHJTNGdhRz…

Google News Fri, 24 Apr 2026

Freedom Broker downgrades TruBridge stock rating on IKS Health deal - Investing.com

<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxQaFVFTEg0b1psbmZZcU0yMFV5VVVsZmVtSjlVZ2RCcHhCQjBmR3F3TjN1Y1dvMDg1MXZ2MVRDd1BlVlRlSjlXQnRUWndKQkdoYUhFeE5YWEhYeHRFSm9SS2I0cmx6VTY0eC1UcGUzZGkwUGJRWC1JcEh6UGtwczN4NHUzbGl0RHBhcmN6MU…

Google News hu, 09 Jul 2026

IKS Health Beefs Up Its Tech Stack with $557M Acquisition of TruBridge - MedCity News

<a href="https://news.google.com/rss/articles/CBMiggFBVV95cUxPUjF6QmUzQnpabVFkY0RNem93RGVtakdiWnpmXzhxTDJoeU15R2pHZElQUjhhVTZvbjctVW5udVhvaWlIcDdWcEJOU1VzU2Y4VWpjS2JYWlp5OWZXV1dPYnhoNEFlamh4MGg2SVNqUGVYcGRDNVdWREhpSGJGWTBFY3J3?oc=5" target=…

IKS — Frequently Asked Questions

What is the current share price of INVENTURUS KNOWLEDGE SO L (IKS)?

As of 2026-09-08 04:53 IST, INVENTURUS KNOWLEDGE SO L (IKS) trades at ₹1,759.90 on NSE. Its 52-week range is ₹1,274.90 to ₹1,928.10.

What is the market capitalisation of IKS?

INVENTURUS KNOWLEDGE SO L (IKS) has a market capitalisation of ₹30,195.16 Cr on NSE.

What is the P/E ratio of IKS?

IKS trades at a trailing price-to-earnings (P/E) ratio of 41.64. The industry average P/E is 41.64. Its price-to-book (P/B) ratio is 10.38.

What is the return on equity (ROE) of IKS?

IKS has a return on equity (ROE) of 25.77%. Its return on capital employed (ROCE) is 29.57%.

Is IKS a good stock to buy?

This page provides a data-driven analysis of INVENTURUS KNOWLEDGE SO L (IKS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space